
Maryanne Demasi, reports
Independent medical journalism
By registering you agree to Substack's Terms of Service, our Privacy Policy, and our Information Collection Notice

Is the FDA “doubling down” on a failed strategy?This is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Last Thursday, the FDA convened its Vaccines and Related Biological Products Advisory Committee (VRBPAC) to discuss the future of covid vaccines.